Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Titan Pharma (TTNP) Tops Q3 EPS by 3c
November 14, 2019 4:05 PM ESTTitan Pharma (NASDAQ: TTNP) reported Q3 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $947 thousand versus the consensus estimate of $700 thousand.
Third Quarter 2019 and Recent Business Highlights
In July 2019, Titan announced a specialty product distribution agreement for Probuphine® (buprenorphine) implants with CVS Caremark, a subsidiary of CVS Health.In August 2019, Titan completed a $2.1 million offering resulting in net cash proceeds of approximately $1.8 million.In September, 2019, the National Institutes of Health's National Institute on Drug Abuse ("NIDA") approved approximately $6.1 million in second-year funding for Titan's... More